For example, an RNA-based therapeutic targeting proteolipid protein 1 (PLP1), the gene defective in Pelizaeus-Merzbacher disease (PMD), has been investigated. This evidence concerns the gene PLP1 and Pelizeaus-Merzbacher spectrum disorder.